Download MendeleyDesign and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.
Jones, P., Storer, R.I., Sabnis, Y.A., Wakenhut, F.M., Whitlock, G.A., England, K.S., Mukaiyama, T., Dehnhardt, C.M., Coe, J.W., Kortum, S.W., Chrencik, J.E., Brown, D.G., Jones, R.M., Murphy, J.R., Yeoh, T., Morgan, P., Kilty, I.(2017) J Med Chem 60: 767-786
- PubMed: 27983835
- DOI: https://doi.org/10.1021/acs.jmedchem.6b01634
- Primary Citation of Related Structures:
5TQ3, 5TQ4, 5TQ5, 5TQ6, 5TQ7, 5TQ8 - PubMed Abstract:
By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.
Organizational Affiliation:
Medicine Design, ‡Pharmacokinetics, Dynamics and Metabolism, and §Inflammation and Immunology Research Unit, Pfizer Inc. , 610 Main Street, Cambridge, Massachusetts 02139, United States.
